Programs & products

Sanofi gains exclusive license to Innate’s B7H3 ANKET TM program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all development, manufacturing and...

Lacutamab demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with advanced Sézary syndrome In addition, Innate’s ANKET TM (Antibody...

Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Preliminary Sezary syndrome lacutamab...

Innate will share preliminary results of the cohort evaluating lacutamab in Sezary syndrome patients post-mogamulizumab from the ongoing TELLOMAK Phase 2 trial Chief Scientific Officer, Eric Vivier...

Preliminary data set presented at EORTC CLTG annual meeting confirms clinical activity and favorable safety profile of lacutamab in patients with mycosis fungoides who express KIR3DL2 and who were...

Monalizumab and IPH5201 developed in collaboration with AstraZeneca advanced into Phase 3 and 2 clinical trials in lung cancer, triggering $55M in milestone payments Second preclinical asset based on...

Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that a planned futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca...

IPH6401/SAR’514 is a BCMA-targeting NK cell engager using Sanofi’s proprietary CROSSODILE ® multi-functional platform. It was developed jointly and benefits from the dual NK targeting of Innate’s...

First patient dosed in monalizumab Phase 3 lung cancer trial, PACIFIC-9 sponsored by AstraZeneca, which triggered a $50 million milestone payment extending Company cash runway into 2024 Monalizumab...